Bibliography
- Cardiovascular disease. Available from: http://www.who.int/cardiovascular_diseases/en/ [Last accessed 17 May 2013]
- Pammolli F, Magazzani L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10(6):428-38
- Scannell JW, Blanckley A, Bolden H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11(3):191-200
- Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012;11(1):17-18
- Muller A. 2011 in reflection. Nat Rev Drug Discov 2012;11(1):6-8
- Zhang XS, Xiang BR. Discontinued drugs in 2007: cardiovascular drugs. Expert Opin Investig Drugs 2008;17(12):1817-28
- Zhang XS, Xiang BR. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 2009;18(7):875-85
- Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: cardiovascular drugs. Expert Opin Investig Drugs 2011;20(10):1311-25
- Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs 2012;21(10):1449-62
- 2012 First Half Financial Results. Available from: http://www.nicox.com/uploads/default/files//HY20120727EN1.pdf [Last accessed 18 May 2013]
- Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro™ and announces changes to management. Available from: http://files.shareholder.com/downloads/ABEA-4J4LWA/1879740064x0x571368/19fd6e2a-c671-49aa-bd75-5bfddaa79103/230512%20Veloxis%20Announces%20Restructuring%20of%20Company.pdf [Last accessed 18 May 2013]
- Development activities. Available from: http://www.takeda.com/company/publications/pdf/index/pipeline_20121031_en.pdf [Last accessed 19 May 2013]
- Company presentation, Roche, 12 Apr 2012. Available from: http://www.roche.com/irp1q12e-a.pdf [Last accessed 19 May 2013]
- Roche Investor Presentation Q1 2011 Sales. Available from: http://www.roche.com/irp1q11e.pdf [Last accessed 19 May 2013]
- Company presentation, Roche, 12 Apr 2012. Available from: http://www.roche.com/irp1q12e-a.pdf [Last accessed 19 May 2013]
- Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01197391?term=REGN-728&rank=1 [Last accessed 19 May 2013]
- Form 10-Q, Regeneron, 24 Oct 2012. Available from: http://sec.gov/Archives/edgar/data/872589/000153217612000004/regn-93012x10q.htm#sBD24B4DD64FB210E0CBD7374D5F26B40 [Last accessed 19 May 2013]
- Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010;53(16):5979-6002
- Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00856258&Search=Search [Last accessed 19 May 2013]
- Company pipeline, Pfizer, 8 Nov 2012. Available from: http://www.pfizer.com/files/research/pipeline/2012_1108/pipeline_2012_1108.pdf [Last accessed 19 May 2013]
- Company pipeline, Mitsubishi, 8 May 2012. Available from: http://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1203.pdf [Last accessed 19 May 2013]
- Company presentation, Cardiome, Apr 2012. Available from: http://cardiome.com/sites/default/files/financials/pdf/FINAL%20MD%26A%20FY%202011.pdf [Last accessed 19 May 2013]
- Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure. Available from: http://clinicaltrials.gov/ct2/show/NCT01092325?term=CXL-1020&rank=2 [Last accessed 20 May 2013]
- A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure. Available from: http://clinicaltrials.gov/ct2/show/NCT01096043?term=CXL-1020&rank=1 [Last accessed 21 May 2013]
- IMPACTS Trial. Investigation of the Modulation of Phospholipase in Acute Chest Syndrome. Available from: http://clinicaltrials.gov/ct2/show/NCT00434473?term=AN-SCD1121&rank=1 [Last accessed 21 May 2013]
- A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects. Available from: http://ichgcp.net/clinical-trials-registry/NCT01522196 [Last accessed 29 July 2013]
- Tezosentan in Patients With Pulmonary Arterial Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT01094067?term=NCT01094067&rank=1 [Last accessed 21 May 2013]
- Tezosentan in Pulmonary Arterial Hypertension. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01077297?term=NCT01077297&rank=1 [Last accessed 22 May 2013]
- Phase III clinical trial of veletri for the treatment of acute heart failure symptoms does not meet primary efficacy objective. Available from: http://www1.actelion.com/en/investors/media-releases/index.page?newsId=1211970 [Last accessed 22 May 2013]
- Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT00793234?term=NCT00793234&rank=1 [Last accessed 24 July 2013]
- Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT01344954?term=NCT01344954&rank=1 [Last accessed 24 July 2013]
- Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE. Available from: http://www.news-medical.net/news/20111217/Enrollment-complete-in-ThromboGenics-BioInvent-TB-402-Phase-IIb-trial-on-VTE.aspx [Last accessed 23 May 2013]
- BioInvent, Thrombo Genics announce results from TB-402 Phase IIb trial on VTE. Available from: http://www.news-medical.net/news/20120605/BioInvent-ThromboGenics-announce-results-from-TB-402-Phase-IIb-trial-on-VTE.aspx [Last accessed 24 July 2013]
- Form 10K, Spherix, 29 Mar 2012. Available from: http://www.sec.gov/Archives/edgar/data/12239/000110465912022224/a12-1151_110k.htm [Last accessed 30 July 2013]
- Spherix's 2010 Annual Shareholder Meeting Script. Available from: http://www.spherix.com/documents/MeetingScript2010_000.pdf [Last accessed 23 May 2013]
- Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10(2):109-34
- Spherix Incorporated (Nasdaq: SPEX) January 2011. Available from: http://www.spherix.com/documents/SPEXCorporatePresentation1-11-FINAL.pdf [Last accessed 23 May 2013]
- Japan Tobacco Inc. Clinical development (as of October 31, 2011). Available from: http://www.jt.com/investors/results/pharmaceuticals/pdf/P.L.20111031_E.pdf [Last accessed 23 May 2013]
- A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER). Available from: http://clinicaltrials.gov/ct2/show/NCT01258907?term=NCT01258907&rank=1 [Last accessed 24 July 2013]
- Announcement of topline results from the GLACIER study. Available from: http://www.bioinvent.com/investors/press-releases/release.aspx?releaseid=682959 [Last accessed 23 May 2013]
- BioInvent Reports Positive Phase I Results for BI-204, in development for prevention of cardiovascular conditions associated with atherosclerosis. Available from: http://www.bioinvent.com/media-centre/press-releases/release.aspx?releaseid=424533
- A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01396226?term=AZD-2927&rank=2§=X3015#evnt [Last accessed 28 May 2013]
- MeltDose® Technology Platform. Available from: http://www.veloxis.com/technology.cfm [Last accessed 29 May 2013]
- Pharmaceutical compositions comprising fenofibrate and atorvastatin. Available from: http://www.freshpatents.com/Pharmaceutical-compositions-comprising-fenofibrate-and-atorvastatin-dt20070118ptan20070014846.php [Last accessed 29 May 2013]
- LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II Clinical Program. Available from: http://www.drugs.com/clinical_trials/lifecycle-pharma-announces-positive-data-lcp-atorfen-phase-ii-clinical-program-4190.html
- Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro™ and announces changes to management. Available from: http://files.shareholder.com/downloads/ABEA-4J4LWA/1879740064x0x571368/19fd6e2a-c671-49aa-bd75-5bfddaa79103/230512%20Veloxis%20Announces%20Restructuring%20of%20Company.pdf [Last accessed 30 July 2013]
- Eisai heart drug looks safe in mid-stage trials. Available from: http://www.reuters.com/article/2010/08/30/heart-eisai-idUSLDE67T0IH20100830 [Last accessed 6 June 2013]
- A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock. Available from: http://clinicaltrials.gov/ct2/show/NCT01145560?term=NCT01145560&rank=1 [Last accessed 24 July 2013]
- BTG Announces Data from Phase IIb Study of AZD9773. Available from: http://www.btgplc.com/page/21061/media/press-releases/2012/btg-announces-data-from-phase-iib-study-of-azd9773 [Last accessed 6 June 2013]
- Essential Hypertension (REDUCE-1). Available from: http://clinicaltrials.gov/ct2/show/NCT01264692?term=NCT01264692&rank=1 [Last accessed 24 July 2013]
- Actelion announces first quarter 2012 financial results. Available from: http://www.actelion.com/en/investors/media-releases/index.page?newsId=1603781 [Last accessed 6 June 2013]
- TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00899977?term=NCT00899977&rank=1 [Last accessed 24 July 2013]
- TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00899977?term=TC-5214&rank=7 [Last accessed 7 June 2013]
- AstraZeneca updates on olaparib and TC-5214 development programmes. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-development [Last accessed 30 July 2013]
- Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20032012tc5214-failed-phase-iii-endpoint [Last accessed 6 June 2013]
- Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A(2) (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009;373(9664):649-58
- Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board. Available from: http://cn.reuters.com/article/pressRelease/idUS238189+09-Mar-2012+PRN20120309?symbol=ANTH.OQ [Last accessed 7 June 2013]
- Form 10-Q, Merck, 9 Nov 2012. Available from: http://www.sec.gov/Archives/edgar/data/310158/000119312512463586/d400394d10q.htm [Last accessed 14 June 2013]
- Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect in Chronic Heart Disease. Available from: http://cn.reuters.com/article/pressRelease/idUS124947+03-Sep-2008+GNW20080903?sp=true [Last accessed 30 July 2013]
- Carney DH, Olszewska-Pazdrak B. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother 2008;9(15):2717-26
- Capstone Therapeutics Announces Operational Update. Available from: http://files.shareholder.com/downloads/OLGC/1650916856x0x535254/6a0b4efc-de04-405f-84f7-4810ead2d08d/CAPS_News_2012_1_20_General_Releases.pdf [Last accessed 14 June 2013]
- Efficacy Study of Iferanserin to Treat Hemorrhoids. Available from: http://clinicaltrials.gov/ct2/show/NCT01483833?term=NCT01483833&rank=1 [Last accessed 24 July 2013]
- Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease. Available from: http://investor.ventrusbio.com/releasedetail.cfm?ReleaseID=639247 [Last accessed 27 July 2013]
- S-1/A 1 v196825_s1a.htm. Available from: http://www.sec.gov/Archives/edgar/data/1426800/000114420410052266/v196825_s1a.htm [Last accessed 13 June 2013]
- Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids (VEN309). Available from: http://clinicaltrials.gov/ct2/show/NCT01355874?term=NCT01355874&rank=1 [Last accessed 24 July 2013]
- Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease. Available from: http://investor.ventrusbio.com/releasedetail.cfm?ReleaseID=686060 [Last accessed 13 June 2013]
- Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care (AKKA). Available from: http://clinicaltrials.gov/ct2/show/NCT01410383?term=NCT01410383&rank=1 [Last accessed 24 July 2013]
- KARO BIO TERMINATES THE EPROTIROME PROGRAM. Available from: http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=639535 [Last accessed 13 June 2013]
- Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT). Available from: http://clinicaltrials.gov/ct2/show/NCT00990327?term=NCT00990327&rank=1 [Last accessed 24 July 2013]
- Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT2). Available from: http://clinicaltrials.gov/ct2/show/NCT01313572?term=NCT01313572&rank=1 [Last accessed 24 July 2013]
- A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress. Available from: http://clinicaltrials.gov/ct2/show/NCT00380198?term=NCT00380198&rank=1 [Last accessed 24 July 2013]
- A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography. Available from: http://clinicaltrials.gov/ct2/show/NCT00162084?term=NCT00162084&rank=1 [Last accessed 24 July 2013]
- Forest Laboratories 2012 Annual Report. Available from: http://investor.frx.com/sites/frx.investorhq.businesswire.com/files/report/file/Full_Report.pdf [Last accessed 10 June 2013]
- Branca MA. Academia given a helping hand in drug development. Nat Rev Drug Discov 2006;5:177
- Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13:913-16
- Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 2008;7:197-8
- Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemp Clin Trials 2010;31:419-22
- Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011;57:153-60